BCM
CADL icon

Boreal Capital Management’s Candel Therapeutics CADL Stock Holding History

Boreal Capital Management’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$78.4K Hold
16,000
– – 0.06% 166
2025
Q4 		$90.4K Hold
16,000
– – 0.07% 165
2025
Q3 		$81.6K Hold
16,000
– – 0.07% 181
2025
Q2 		$81K Buy
+16,000
New +$82.3K 0.07% 181

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Boreal Capital Management's CADL Position: Q1 2026 in Review

Boreal Capital Management held its Candel Therapeutics (CADL) position steady in Q1 2026 at 16,000 shares worth $78.4K. The position accounts for 0.06% of the portfolio, ranked #166.

Boreal Capital Management first reported a position in CADL in Q2 2025 and has held it in 4 quarters since. The position peaked at $90.4K in Q4 2025. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • Boreal Capital Management held 16,000 shares of Candel Therapeutics worth $78.4K as of Q1 2026.
  • Boreal Capital Management left its Candel Therapeutics share count unchanged in Q1 2026.
  • Candel Therapeutics made up 0.06% of Boreal Capital Management's portfolio in Q1 2026, its #166 holding.
  • Boreal Capital Management first reported a position in Candel Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Boreal Capital Management's Candel Therapeutics position peaked at $90.4K in Q4 2025.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Boreal Capital Management's 13F filing for Q1 2026, filed 14 May 2026.